A Phase II Trial of Revlimid and 'On Demand' Dexamethasone Dosing in Patients With Newly Diagnosed Symptomatic Multiple Myeloma.

Next Previous
Trial Profile

A Phase II Trial of Revlimid and 'On Demand' Dexamethasone Dosing in Patients With Newly Diagnosed Symptomatic Multiple Myeloma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Dexamethasone (Primary) ; Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Biomarker; Therapeutic Use

    • Most Recent Events

    • 28 Aug 2017 Planned End Date changed from 1 May 2017 to 1 May 2018.
    • 10 Oct 2016 Planned End Date changed from 1 May 2016 to 1 May 2017.
    • 04 Feb 2016 Planned End Date changed from 1 Oct 2015 to 1 May 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top